Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.55 |
| ▸ | TYMP | P19971 | 5/20 | 0.47 |
| ▸ | TK1 | P04183 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25504793 | 0.86 | TK2 (0.58) | TK2TYMPTK1ALDH1A1LMNA | |
| SCHEMBL19224116 | 0.86 | TK2 (0.58) | TK2TYMPTK1ALDH1A1LMNA | |
| SCHEMBL9650588 | 0.85 | TK2 (0.55) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL2585241 | 0.85 | TK2 (0.55) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL18750458 | 0.83 | TK2 (0.56) | TK2TYMPTK1ALDH1A1LMNA | |
| SCHEMBL16940274 | 0.83 | TK2 (0.55) | TK2TYMPTK1ALDH1A1LMNA | |
| SCHEMBL15434595 | 0.83 | TK2 (0.55) | TK2TYMPTK1ALDH1A1LMNA | |
| SCHEMBL16923193 | 0.82 | PYGM (0.56) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL10226146 | 0.82 | PYGM (0.56) | TK2TYMPALDH1A1LMNAALB | |
| SCHEMBL18750451 | 0.82 | TK2 (0.54) | TK2TYMPTK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | DUT, UNG, GALE | TK2 171/4885TYMP 5/4885TK1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.